Hussman Strategic Advisors’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-14,700
| Closed | -$4.22M | – | 331 |
|
|
2025
Q2 | $4.22M | Buy |
14,700
+2,100
| +17% | +$628K | 0.97% | 16 |
|
|
2025
Q1 | $3.88M | Buy |
12,600
+4,200
| +50% | +$1.44M | 0.94% | 12 |
|
|
2024
Q4 | $2.96M | Buy |
8,400
+2,100
| +33% | +$772K | 0.88% | 20 |
|
|
2024
Q3 | $2.26M | Buy |
+6,300
| New | +$2.13M | 0.55% | 77 |
|
|
2023
Q3 | – | Sell |
-9,300
| Closed | -$2.05M | – | 322 |
|
|
2023
Q2 | $2.05M | Buy |
+9,300
| New | +$2.06M | 0.38% | 116 |
|
|
2022
Q1 | – | Sell |
-2,600
| Closed | -$562K | – | 351 |
|
|
2021
Q4 | $562K | Sell |
2,600
-500
| -16% | -$98.2K | 0.12% | 234 |
|
|
2021
Q3 | $572K | Sell |
3,100
-4,100
| -57% | -$808K | 0.13% | 222 |
|
|
2021
Q2 | $1.29M | Sell |
7,200
-3,600
| -33% | -$686K | 0.27% | 151 |
|
|
2021
Q1 | $1.81M | Buy |
10,800
+600
| +6% | +$100K | 0.37% | 96 |
|
|
2020
Q4 | $1.55M | Sell |
10,200
-15,300
| -60% | -$2.01M | 0.41% | 99 |
|
|
2020
Q3 | $2.58M | Buy |
+25,500
| New | +$2.8M | 0.68% | 31 |
|
|
2019
Q4 | – | Sell |
-10,000
| Closed | -$798K | – | 235 |
|
|
2019
Q3 | $798K | Sell |
10,000
-15,000
| -60% | -$1.21M | 0.23% | 146 |
|
|
2019
Q2 | $1.95M | Hold |
25,000
| – | – | 0.55% | 80 |
|
|
2019
Q1 | $2.93M | Buy |
+25,000
| New | +$2.91M | 0.72% | 39 |
|
|
2018
Q1 | – | Sell |
-10,000
| Closed | -$1.48M | – | 244 |
|
|
2017
Q4 | $1.48M | Sell |
10,000
-15,000
| -60% | -$1.91M | 0.42% | 94 |
|
|
2017
Q3 | $2.93M | Sell |
25,000
-250
| -1% | -$31.9K | 0.71% | 54 |
|
|
2017
Q2 | $3.28M | Sell |
25,250
-250
| -1% | -$31.2K | 0.73% | 61 |
|
|
2017
Q1 | $3.45M | Buy |
+25,500
| New | +$3.86M | 0.76% | 61 |
|
|
2015
Q4 | – | Sell |
-25,000
| Closed | -$3.28M | – | 242 |
|
|
2015
Q3 | $3.28M | Hold |
25,000
| – | – | 0.42% | 102 |
|
|
2015
Q2 | $4.35M | Hold |
25,000
| – | – | 0.5% | 80 |
|
|
2015
Q1 | $4.31M | Sell |
25,000
-25,000
| -50% | -$3.81M | 0.45% | 88 |
|
|
2014
Q4 | $6.47M | Hold |
50,000
| – | – | 0.64% | 68 |
|
|
2014
Q3 | $6.43M | Sell |
50,000
-84,000
| -63% | -$8.66M | 0.55% | 76 |
|
|
2014
Q2 | $11.9M | Hold |
134,000
| – | – | 0.91% | 45 |
|
|
2014
Q1 | $12.6M | Hold |
134,000
| – | – | 0.94% | 46 |
|
|
2013
Q4 | $15.2M | Sell |
134,000
-224,000
| -63% | -$20.2M | 1.08% | 33 |
|
|
2013
Q3 | $28.2M | Sell |
358,000
-110,000
| -24% | -$8.04M | 1.55% | 4 |
|
|
2013
Q2 | $30.8M | Buy |
+468,000
| New | +$30.1M | 1.4% | 11 |
|
Other funds holding UTHR
ACA
DGM
Hussman Strategic Advisors's UTHR Position: Q3 2025 in Review
Hussman Strategic Advisors sold out of United Therapeutics (UTHR) in Q3 2025, closing a stake of 14,700 shares — an estimated $4.22M sold.
Hussman Strategic Advisors first reported a position in UTHR in Q2 2013 and held it in 28 quarters. The position peaked at $30.8M in Q2 2013. 707 funds tracked by Wall St. Rank hold UTHR as of Q3 2025.
- Hussman Strategic Advisors reported no remaining United Therapeutics position as of Q3 2025 after selling out during the quarter.
- Hussman Strategic Advisors sold 14,700 United Therapeutics shares in Q3 2025, an estimated $4.22M.
- Hussman Strategic Advisors first reported a position in United Therapeutics in Q2 2013 and held it in 28 quarters.
- Hussman Strategic Advisors's United Therapeutics position peaked at $30.8M in Q2 2013.
- 707 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2025.
Based on Hussman Strategic Advisors's 13F filing for Q3 2025, filed 3 Nov 2025.